TY - JOUR T1 - Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer. AU - Reznik,Y, AU - Chapon,F, AU - Lahlou,N, AU - Deboucher,N, AU - Mahoudeau,J, PY - 1997/12/31/pubmed PY - 1997/12/31/medline PY - 1997/12/31/entrez SP - 566 EP - 8 JF - Journal of endocrinological investigation JO - J Endocrinol Invest VL - 20 IS - 9 N2 - Treatment of prostatic cancer with GnRH agonist is a medical alternative to surgical castration, although hyperstimulation of the tumor can occur. We describe an unusual unwanted effect of such a treatment which unmasked a clinically silent gonadotroph adenoma. A 62-year-old man developed after the first injection of leuprorelin-depot a sudden intracranial hypertension, which was related to apoplexy of an unknown pituitary adenoma. Its gonadotroph origin was recognized after surgery by immunocytochemistry. Retrospectively, the tumor was shown to secrete in vivo both FSH and LH when on therapy with the agonist, demonstrating the lack of desensitization. Testosterone levels were also markedly and sustainly high when on therapy, a particularly unwanted effect in prostatic cancer. As gonadotroph adenomas occur in men in the same age group as prostatic cancer, the question is raised whether hormonal testing and pituitary imaging should be performed before starting a therapy with GnRH agonist in men. SN - 0391-4097 UR - https://www.unboundmedicine.com/medline/citation/9413812/Pituitary_apoplexy_of_a_gonadotroph_adenoma_following_gonadotrophin_releasing_hormone_agonist_therapy_for_prostatic_cancer_ L2 - https://link.springer.com/article/10.1007/BF03348020 DB - PRIME DP - Unbound Medicine ER -